I will state that I am in a qualified agreement with you here.
I think some of the gain could hold. However that ~150% gain won't hold unless something interesting - and positive - were to happen.
The old MERS-cide from several years back - could be dusted off and 'might' be useful - but with the current state of the company and its finances, and with the need to focus on the anti-herpes virus treatments, that's not something that the company would be able to roll out anyway in anything resembling less than a few years.
If the ligands that were drafted back then to deal with MERS were to be similar enough to those that the new coronavirus has,... then it might be effect as a treatment,... IF it could be built into a nanoviriscide.
I think we see this share price settle back down quite a bit in the near term.